October 02, 2014 4:31 AM ET


Company Overview of Philogen S.p.A.

Company Overview

Philogen S.p.A., a biotechnology company, is engaged in the discovery and development of biopharmaceutical products for the treatment of certain diseases that are characterized by angiogenesis, the proliferation of newly formed blood vessels. The company focuses on delivering bioactive agents, such as cytokines, radionuclides, or drugs to the site of disease using antibodies and ligands that specifically target stromal antigens. It develops anti-cancer antibody derivatives and antibody-derivatives for the treatment of rheumatoid arthritis. Its products include DARLEUKIN (L19-IL2), Teleukin, and Fibromun (L19-TNF) that are human vascular targeting immunocytokine. The company also develops L19...

Via Bellaria, 35

Sovicille, SI 53018


Founded in 1996


39 057 717816


39 0577 1781 680

Key Executives for Philogen S.p.A.

Age: 51
Vice President and Director
Compensation as of Fiscal Year 2014.

Philogen S.p.A. Key Developments

Philogen S.p.A. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013

Philogen S.p.A. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

Actinium Pharmaceuticals, Inc. and Philogen S.P.A. Announce Start of Pre-Clinical Development of an Alpha Therapy Based Antiangiogenesis Program

Actinium Pharmaceuticals, Inc. and Philogen S.p.A. announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody targets newly formed blood vessels that otherwise allow cancers to grow. Clinical trials of drug candidates based on alpha emitting isotopes have so far demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. Actinium Pharmaceuticals and Philogen intend to add antiangiogenesis to this growing field of use of alpha emitters. Antiangiogenesis is a successful approach to treating numerous cancer types. Currently approved antiangiogenesis drugs act mostly by interfering with the signaling pathway used by cancer cells to stimulate growth of blood vessels. In many cases, cancer cells eventually find alternative ways to spur blood vessel growth. In contrast, Philogen's L19 targets adhesion molecules that anchor blood vessel cells which makes it less susceptible to cancer controlled pathways. Depending on the architecture of vasculature and its proximity to cancer stem cells, actinium 225 coupled with L19 could potentially offer an effective combination of properties tailor made for certain solid cancer types. The first model under consideration is glioblastoma multiforme, a difficult to treat form of brain cancer.

Philogen S.p.A. Presents at BIO-Europe 2012, Nov-12-2012

Philogen S.p.A. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.

Similar Private Companies By Industry

Company Name Region
Archimede Ricerche S.r.l. Europe
Bionica Tech s.r.l Europe
Tissuelab S.p.A. Europe
Tecnogen S.p.A. Europe
Erydel s.r.l. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Philogen S.p.A., please visit www.philogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.